A recent study published in Cancer Research by scientists at The University of Texas MD Anderson Cancer Center (USA) and collaborators aimed to identify and characterize a target that elicits an anticancer response through both disrupting cancer cell redox homeostasis and increasing the immunogenicity of pancreatic ductal adenocarcinoma (PDAC).
Lysine demethylase 4C (KDM4C) is a chromatin-modifying protein frequently overexpressed across multiple solid and hematological cancers (including breast, lung, colon, prostate, esophageal cancers and lymphomas) and has been linked to chromatin instability and enhanced cell proliferation and stem cell-like behavior.
Researchers have developed an innovative immunotoxin (a fusion protein called GrB-Fc-KS49) designed to target epithelial membrane protein-2 (EMP2), a biomarker overexpressed in more than 75% of breast cancer cases, including triple-negative breast cancer (TNBC).
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
Eterna Therapeutics Inc. has announced plans to evaluate the ability of ERNA-101 to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The University of Texas MD Anderson Cancer Center.
Investigators at Nanjing Medical University and The University of Texas MD Anderson Cancer Center recently published data from their research that aimed to identify novel immunotherapy targets in triple-negative breast cancer (TNBC).
At this week’s American Society for Radiation Oncology meeting, scientists from The University of Texas MD Anderson Cancer Center reported the discovery and preclinical evaluation of CD47-LLO, a novel microbial-inspired antibody-drug conjugate (ADC) for the treatment of cancer.
Scientists from Abbvie Inc. and the Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center have discovered a new allosteric MALT1 inhibitor, ABBV-MALT1, for the treatment of certain types of diffuse large B-cell lymphoma (DLBCL).
Sibylla Biotech SpA and the University of Texas MD Anderson Cancer Center have signed a strategic collaboration agreement to discover and develop novel small molecule folding interfering degraders (FIDs) for the treatment of cancer.
Replay Holdings LLC and The University of Texas MD Anderson Cancer Center report that the FDA has cleared the IND application for PRAME TCR/IL-15 NK (SY-307), an engineered T-cell receptor natural killer (TCR-NK) cell therapy for relapsed/refractory myeloid malignancies.
